Earnings Releases·Nov 4, 2026, 4:19 PM ET

Zomedica — Third Quarter 2026 Earnings Summary

Consolidated revenue reached $9.9 million for the quarter (up 22% YoY) and $28.2 million year-to-date (up 31% YoY), while net loss narrowed to $3.2 million for the quarter (down 48% YoY) and $11.5 million for the nine months, excluding a $55.8 million non-cash impairment charge from the prior year.
Operating expenses declined 21% to $9.5 million in the quarter, and cash burn improved 32% to $3.2 million, marking the lowest third-quarter burn on record with total liquidity of $40.9 million.
Diagnostic revenue surged 113% YoY to $1.6 million, and consumables grew 26% to $6.8 million, contributing to a 23rd consecutive quarter of year-over-year revenue growth.
Management expressed confidence in closing the year strong based on record revenue and disciplined spending, with no specific financial guidance changes or M&A announcements detailed in the summary.